NGEN net incomeFY2025-C$44.12M
NGEN net income was -C$44.12M for fiscal 2025 (ended Dec 31, 2025), compared with -C$24.25M in fiscal 2024.
NervGen Pharma Corp. (NGEN) financials
For fiscal 2025 (ended Dec 31, 2025), NervGen Pharma Corp. reported -C$44.12M of net income. Figures are in CAD, the currency of its SEC filings.
- Net income, FY2025
- -C$44.12M
- EPS, diluted, FY2025
- -C$0.61
- Cash
- C$22.07M
FY2024FY2025
NGEN revenue and earnings growth
NGEN EPSFY2025-C$0.61
NGEN diluted EPS was -C$0.61 for fiscal 2025 (ended Dec 31, 2025), compared with -C$0.36 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Research and development | C$13.91M | C$15.81M |
| Selling, general and admin | C$11.17M | C$9.37M |
| Net income | -C$44.12M | -C$24.25M |
| EPS, basic | -C$0.61 | -C$0.36 |
| EPS, diluted | -C$0.61 | -C$0.36 |
| Diluted shares | 72.3M | 67.3M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash and equivalents | C$22.07M | C$17.27M |
| Receivables | C$80.8K | C$415.3K |
| Current assets | C$22.80M | C$19.01M |
| Total assets | C$23.21M | C$19.49M |
| Current liabilities | C$19.73M | C$16.90M |
| Total liabilities | C$19.73M | C$16.91M |
| Shareholders' equity | C$3.48M | C$2.58M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Operating cash flow | -C$19.50M | -C$16.84M |
| Investing cash flow | C$100.9K | C$58.9K |
| Financing cash flow | C$23.76M | C$22.70M |
| Stock-based compensation | C$5.39M | C$6.04M |
Key ratios
Source: XBRL data NervGen Pharma Corp. files with the SEC, latest filing dated Mar 31, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
NGEN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NGEN | - | - | -C$44.12M | - | $143.1M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
NGEN FAQ
5 questionsIs NGEN profitable?
No. NervGen Pharma Corp. reported a net loss of C$44.12M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does NGEN have?
NervGen Pharma Corp. reported C$22.07M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is NGEN earnings per share?
Diluted earnings per share were -C$0.61 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did NGEN last report financial results?
The latest statements here come from NervGen Pharma Corp.'s 40-F filed on Mar 31, 2026, covering the period ended Dec 31, 2025.Where does this NGEN financial data come from?
Quantisnow builds these statements from the structured XBRL data NervGen Pharma Corp. files with the SEC. It is provided for information only and is not investment advice.